Sunday, January 08, 2012

Stem Cell Stocks

On Sunday evening, 60 Minutes broadcast an extensive report on stem cell scams. It reported on companies around the world that make outrageous claims with regards to the treatment and cures that stem cells can provide. Numerous people who have incurable diseases are desperately looking for cures, and are being taking advantage of by charlatans purporting to solve all their medical issues.

However, stem cells are being used currently for medical treatments. Look at bone marrow transplants that are used to treat leukemia utilizing adult stem cells. Scientists are actively looking at stem cells to treat diseases such as cancer, Parkinson's disease, and spinal cord injuries.

There are actually many publicly traded companies involved in stem cell research. has turned up over 20 stem cell stocks, half of which are currently profitable.

Integra Lifesciences Holdings (IART) is a New Jersey based company that develops, manufactures, and sells medical devices, implants, biomaterials, and instruments to the stem cell, surgery, and soft tissue repair markets. The stock trades at 17 times current earnings, and 7.5 times forward earnings. However, earnings for the latest quarter were down 31.8%.

Alexion Pharmaceuticals (ALXN) is a Connecticut based company with an $13.7 billion market capitalization that is involved in the development of biologic therapeutic products for the treatment of hematologic and cardiovascular disorders, auto-immune diseases, and cancer. The company licenses porcine embryonic stem cells for transgenic animals. The stock has a price to earnings ratio of 92 and a forward PE of 45. Earnings for the latest quarter were up an amazing 135.2% on a 44% rise in revenues.

Cellgene (CELG) is a $29.8 billion market cap company involved in the discovery and production of therapies designed to treat cancer and immune-inflammatory-related diseases. One of the company's main products is Thalomid, which is used for the treatment of erythema nodosum leprosum, a complication of leprosy. They also received a patent on placental stem cell recovery. The stock sports a PE ratio of 28 and a forward PE of 15. Quarterly earnings were up 32.7% on a 37% revenue increase.

For a free list of over twenty stem cell stocks which you can download, sort, and update, go to

Disclosure: Author did not own any of the above at the time the article was written.


1 comment:

Market Research Reports said...
This comment has been removed by a blog administrator.